XML 35 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Long-term debt
6 Months Ended
Jun. 30, 2018
Debt Disclosure [Abstract]  
Long-term debt
Long-term debt
Long-term debt was comprised of the following: 
 
June 30,
2018
 
December 31,
2017
Senior secured credit facilities:
 
 
 
Term Loan A
$
725,000

 
$
775,000

Term Loan A-2
952,000

 

Term Loan B
3,360,000

 
3,377,500

Revolver

 
300,000

Senior notes
4,500,000

 
4,500,000

Acquisition obligations and other notes payable
172,692

 
150,512

Capital lease obligations
292,296

 
297,170

Total debt principal outstanding
10,001,988

 
9,400,182

Discount and deferred financing costs
(57,901
)
 
(63,951
)
 
9,944,087

 
9,336,231

Less current portion
(1,768,514
)
 
(178,213
)
 
$
8,175,573

 
$
9,158,018


Scheduled maturities of long-term debt at June 30, 2018 were as follows: 
2018 (remainder of the year)
95,011

2019
1,712,246

2020
74,792

2021
3,311,046

2022
1,287,741

2023
162,580

Thereafter
3,358,572


On March 29, 2018, the Company entered into an Increase Joinder No. 1 (Increase Joinder Agreement) under its existing senior secured credit facilities. Pursuant to this Increase Joinder Agreement, the Company entered into an additional $995,000 Term Loan A-2. The new Term Loan A-2 bears interest at LIBOR plus an interest rate margin of 1.00%. As of June 30, 2018, the Company had drawn $952,000 of the Term Loan A-2. The remaining amount of $43,000 on Term Loan A-2 was drawn subsequent to June 30, 2018.
During the first six months of 2018, the Company made mandatory principal payments under its senior secured credit facilities totaling $50,000 on Term Loan A and $17,500 on Term Loan B.
As of June 30, 2018, the Company maintains several active and forward interest rate cap agreements that have the economic effect of capping the Company's maximum exposure to LIBOR variable interest rate changes on specific portions of the Company's floating rate debt, as described below. The cap agreements are designated as cash flow hedges and, as a result, changes in the fair values of these cap agreements are reported in other comprehensive income. The amortization of the original cap premium is recognized as a component of debt expense on a straight-line basis over the terms of the cap agreements. The cap agreements do not contain credit-risk contingent features.
On June 30, 2018, the Company's interest rate cap agreements that were entered into in November 2014 with notional amounts totaling $3,500,000 expired. These cap agreements became effective September 30, 2016 and had the economic effect of capping the LIBOR variable component of the Company’s interest rate at a maximum of 3.50% on an equivalent amount of the Company’s debt. During the six months ended June 30, 2018, the Company recognized debt expense of $4,140 from these cap agreements and recorded an immaterial loss in other comprehensive income due to a decrease in unrealized fair value of these cap agreements.
As of June 30, 2018, the Company maintains several currently effective interest rate cap agreements that were entered into in October 2015 with notional amounts totaling $3,500,000. These cap agreements became effective June 29, 2018 and have the economic effect of capping the LIBOR variable component of the Company’s interest rate at a maximum of 3.50% on an equivalent amount of its debt. These cap agreements expire on June 30, 2020. As of June 30, 2018, the total fair value of these cap agreements was an asset of approximately $2,085. During the six months ended June 30, 2018, the Company recorded a gain of $1,053 in other comprehensive income due to an increase in the unrealized fair value of these cap agreements.
The following table summarizes the Company’s derivative instruments outstanding as of June 30, 2018 and December 31, 2017
 
 
June 30, 2018
 
December 31, 2017
Derivatives designated as hedging instruments
 
Balance sheet location
 
Fair value
 
Balance sheet location
 
Fair value
Interest rate cap agreements
 
Other long-term assets
 
$
2,085

 
Other long-term assets
 
$
1,032


 The following table summarizes the effects of the Company’s interest rate cap agreements for the three and six months ended June 30, 2018 and 2017:
 
Amount of unrecognized gains (losses) in OCI on interest rate cap agreements
 
Location of losses reclassified from accumulated OCI into income
 
Amount of losses reclassified from accumulated OCI into income
 
Three months ended
June 30,
 
Six months ended
June 30,
 
 
Three months ended
June 30,
 
Six months ended
June 30,
Derivatives designated as cash flow hedges
2018
 
2017
 
2018
 
2017
 
 
2018
 
2017
 
2018
 
2017
Interest rate cap
agreements
$
(361
)
 
$
(2,969
)
 
$
1,053

 
$
(8,186
)
 
Debt expense
 
$
2,070

 
$
2,070

 
$
4,140

 
$
4,139

Tax benefit
(expense)
93

 
1,154

 
(271
)
 
3,184

 
Tax expense
 
(533
)
 
(805
)
 
(1,066
)
 
(1,610
)
Total
$
(268
)
 
$
(1,815
)
 
$
782

 
$
(5,002
)
 
 
 
$
1,537

 
$
1,265

 
$
3,074

 
$
2,529


As of June 30, 2018, the Company’s Term Loan B debt bears interest at LIBOR plus an interest rate margin of 2.75%. Term Loan B is subject to interest rate caps if LIBOR should rise above 3.50%. Term Loan A bears interest at LIBOR plus an interest rate margin of 2.00%. The capped portion of Term Loan A is $140,000 if LIBOR should rise above 3.50%. In addition, the uncapped portion of Term Loan A, which is subject to the variability of LIBOR, is $585,000. Term Loan A-2 is subject to the variability of LIBOR plus an interest rate margin of 1.00%. Interest rates on the Company’s senior notes are fixed by their terms.
The Company’s weighted average effective interest rate on the senior secured credit facilities at the end of the second quarter was 4.72%, based on the current margins in effect of 2.00% for Term Loan A, 1.00% for Term Loan A-2, and 2.75% for Term Loan B, as of June 30, 2018.
The Company’s overall weighted average effective interest rate during the quarter ended June 30, 2018 was 4.91% and as of June 30, 2018 was 4.99%.
As of June 30, 2018, the Company’s interest rates are fixed on approximately 48.8% of its total debt.
As of June 30, 2018, the Company had undrawn revolving credit facilities totaling $1,000,000, of which approximately $14,355 was committed for outstanding letters of credit. The remaining amount is unencumbered. The Company also has approximately $22,351 of additional outstanding letters of credit related to its Kidney Care business and $211 of committed outstanding letters of credit related to DaVita Medical Group (DMG), which is backed by a certificate of deposit.